Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
News 12.06.2025 Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or “MTx”), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the...